These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1457210)

  • 21. A formalin inactivated whole SIVmac vaccine in Ribi adjuvant protects against homologous and heterologous SIV challenge.
    Putkonen P; Thorstensson R; Cranage M; Nilsson C; Ghavamzadeh L; Albert J; Greenaway P; Biberfeld G
    J Med Primatol; 1992; 21(2-3):108-12. PubMed ID: 1433260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphoproliferative responses in macaques immunized with inactivated SIV vaccine.
    Teng XC; Ashworth LA; Sharpe SA; Dennis MJ; Cranage MP
    AIDS Res Hum Retroviruses; 1993 Aug; 9(8):799-801. PubMed ID: 8217348
    [No Abstract]   [Full Text] [Related]  

  • 23. A formalin inactivated whole SIV vaccine and a glycoprotein-enriched subunit vaccine confers protection against experimental challenge with pathogenic live SIV in rhesus monkeys.
    Murphey-Corb M; Martin LN; Davison-Fairburn B; Montelaro RC; Miller M; West M; Ohkawa S; Baskin GB; Zhang JY; Putney S
    Dev Biol Stand; 1990; 72():273-85. PubMed ID: 2282987
    [No Abstract]   [Full Text] [Related]  

  • 24. Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum.
    Almond N; Rose J; Sangster R; Silvera P; Stebbings R; Walker B; Stott EJ
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1919-22. PubMed ID: 9266988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A formalin-fixed whole SIV vaccine induces protective responses that are cross-protective and durable.
    Murphey-Corb M; Ohkawa S; Davison-Fairburn B; Martin LN; Baskin GB; Langlois AJ; McIntee M; Narayan O; Gardner MB
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1475-8. PubMed ID: 1466986
    [No Abstract]   [Full Text] [Related]  

  • 26. Cell-mediated immune response of macaques immunized with low doses of simian immunodeficiency virus (SIV).
    Dittmer U; Spring M; Petry H; Nisslein T; Rieckmann P; Lüke W; Stahl-Hennig C; Hunsmann G; Bodemer W
    J Biotechnol; 1996 Jan; 44(1-3):105-10. PubMed ID: 8717393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles.
    Mossman SP; Pierce CC; Watson AJ; Robertson MN; Montefiori DC; Kuller L; Richardson BA; Bradshaw JD; Munn RJ; Hu SL; Greenberg PD; Benveniste RE; Haigwood NL
    AIDS Res Hum Retroviruses; 2004 Apr; 20(4):425-34. PubMed ID: 15157361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of protective efficacy of recombinant subunit vaccines against simian immunodeficiency virus infection of macaques.
    Hu SL; Abrams K; Misher L; Stallard V; Moran P; Zarling JM; Langlois AJ; Kuller L; Morton WR; Benveniste RE
    J Med Primatol; 1992; 21(2-3):119-25. PubMed ID: 1433262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge.
    Mattapallil JJ; Hill B; Douek DC; Roederer M
    J Med Primatol; 2006 Aug; 35(4-5):217-24. PubMed ID: 16872285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasmas from lymphocyte- and macrophage-tropic SIVmac-infected macaques have antibodies with a broader spectrum of virus neutralization activity in macrophage versus lymphocyte cultures.
    Zhuge W; Jia F; Adany I; Narayan O; Stephens EB
    Virology; 1997 Jan; 227(1):24-33. PubMed ID: 9007055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Summary of the SIV Working Group.
    Schultz AM
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1439-40. PubMed ID: 1466977
    [No Abstract]   [Full Text] [Related]  

  • 33. The ability of certain SIV vaccines to provoke reactions against normal cells.
    Langlois AJ; Weinhold KJ; Matthews TJ; Greenberg ML; Bolognesi DP
    Science; 1992 Jan; 255(5042):292-3. PubMed ID: 1549775
    [No Abstract]   [Full Text] [Related]  

  • 34. AIDS research. New findings cast doubt on UK vaccine trials.
    Anderson C
    Nature; 1991 Sep; 353(6342):287. PubMed ID: 1822967
    [No Abstract]   [Full Text] [Related]  

  • 35. Anti-cell antibody in macaques.
    Stott EJ
    Nature; 1991 Oct; 353(6343):393. PubMed ID: 1815549
    [No Abstract]   [Full Text] [Related]  

  • 36. [Protection of inventions in the field of vaccines and sera].
    Korovkin VI; Shepelev NP; Dzagurov SG
    Zh Mikrobiol Epidemiol Immunobiol; 1977 May; (5):118-23. PubMed ID: 899417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two Instances of Human Sera showing Abnormal Anti-complementary Power.
    Kennaway EL; Wright AM
    J Hyg (Lond); 1919 Oct; 18(3):255-9. PubMed ID: 20474686
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-Tuberculous Vaccines and Sera.
    Fortescue-Brickdale JM
    Bristol Med Chir J (1883); 1906 Mar; 24(91):1-11. PubMed ID: 28896762
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-Tuberculous Vaccines and Sera.
    Hospital (Lond 1886); 1906 Apr; 40(1022):66. PubMed ID: 29819972
    [No Abstract]   [Full Text] [Related]  

  • 40. SERA AND VACCINES.
    Am J Public Health (N Y); 1923 Jul; 13(7):585. PubMed ID: 18010994
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.